Isomorphic Labs, an AI-driven drug discovery company spun out of Google DeepMind, has secured over $2 billion in a Series B funding round. The substantial investment, led by Thrive Capital, will be used to expand its proprietary drug design engine, IsoDDE, and advance its pipeline of drug candidates toward human clinical trials. The company leverages DeepMind's AlphaFold technology to predict protein structures and design potent, low-side-effect medicines. AI
Summary written by gemini-2.5-flash-lite from 5 sources. How we write summaries →
IMPACT Accelerates AI's role in drug discovery, potentially leading to faster development of new medicines and treatments.
RANK_REASON Significant funding round for an AI-driven drug discovery company with plans for human trials.